Contact Us
Drug Search Results
More Filters [+]

Lebrikizumab

Alternative Names: lebrikizumab, milr1444a, tnx-650, LY3650150, LY 3650150, LY-3650150, EBGLYSS
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Lebrikizumab is a novel, high-affinity, monoclonal antibody or biological agent that selectively inhibits interleukin 13 (IL-13) for the treatment of atopic dermatitis (eczema). (Sourced from: https://dermnetnz.org/topics/lebrikizumab)

Mechanisms of Action: IL13 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: Almirall

Clinical Description

Map of Global Clinical Trials for Lebrikizumab

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, France, Germany, Italy, Japan, Korea, Latvia, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 33

Highest Development Phases

Phase 3: Dermatitis, Atopic|Nasal Polyposis|Rhinitis, Allergic, Perennial|Sinusitis|Skin Diseases, Genetic

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2031240234

P3

Not yet recruiting

Sinusitis|Nasal Polyposis

2027-02-28

J2T-MC-KGBU

P3

Unknown Status

Nasal Polyposis|Sinusitis

2026-10-30

J2T-MC-KGBT

P3

Unknown Status

Rhinitis, Allergic, Perennial

2026-08-03

ADorable-2

P3

Enrolling by invitation

Dermatitis, Atopic

2026-06-26

Recent News Events

Date

Type

Title

12/01/2024

PubMed

 Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.

11/19/2024

News Article

 Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss™ (lebrikizumab)

10/25/2024

News Article

 Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab

10/24/2024

News Article

 Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

10/23/2024

News Article

 LEO Pharma Presents Adbry® (tralokinumab-ldrm) and Delgocitinib Cream Data at 2024 Fall Clinical Dermatology Conference

05/10/2024

PubMed

 Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA).

05/01/2024

PubMed

 The Rebirth of Lebrikizumab for Airway Disease.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions